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Background: Fibromyalgia (FM) syndrome is characterized by widespread pain, fatigue, and 
generalized increased pain sensitivity. Appropriate and simple pain models are methods employed to 
assess pain mechanisms that can potentially lead to improved treatments. Pressure pain thresholds 
(PPTs) or mapping the referred pain area produced by pressure stimulation at suprathreshold 
intensities are used to assess pain mechanisms. The optimal suprathreshold stimulation intensity to 
elicit referred pain with minimal discomfort for patients with FM has yet to be determined.
Objectives: The aim of this study was to compare the area and intensity of pressure-induced 
referred pain in patients with FM as elicited by systematic increases in PPTs, compared with controls. 
Study Design: Observational, crossed-section study.
Setting: Research laboratory. 
Methods: Twenty-six patients with FM and 26 healthy controls, age- and gender-matched, were 
included. Suprathreshold stimulation was applied to the infraspinatus muscle of the dominant side 
at 4 different intensities (PPT +20%, +30%, +40%, and +50%), after which referred pain was 
evaluated by measuring the area of pain in pixels using a digital body chart and its intensity on 
a Visual Analog Scale. Factors related to anxiety condition, pain catastrophizing, depression, and 
quality of life were recorded. 
Results: The referred pain areas were larger in the FM group compared with healthy individuals 
at 120% (P = 0.024), 130% (P = 0.001), 140% (P = 0.001), and 150% (P = 0.001) PPT, however, 
within the FM group no differences were found between the intensity of suprathreshold stimulation 
and the size of the referred pain areas (P = 0.135) or pain intensity (P > 0.05). There was a positive 
correlation between the size of referred pain areas and pain catastrophizing in the FM group (r = 
0.457, P = 0.032). 
Limitations: This study presents some limitations, among which is the variability found in the 
referred pain areas.
Conclusions: These findings show that referred pain induced by applying a suprathreshold 
pressure of 120% PPT can be a useful biomarker to assess sensitized pain mechanisms in patients 
suffering from FM. 
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sensitive to high-pressure stimuli, such as those with FM 
syndrome, have not been tested. Moreover, the optimal 
stimulation intensity to elicit referred pain with mini-
mal discomfort for patients has yet to be determined.
The objective of this study was to compare the 
area and intensity of pressure-induced referred pain in 
patients with FM as elicited by systematic increases in 
PPT compared with controls. The hypotheses were that 
patients with FM (1) would not elicit stepwise increases 
in the area of referred pain when suprathreshold pres-
sure intensities were increased; (2) would experience 
increased pressure pain sensitivity; and (3) would report 




Patients diagnosed with FM syndrome were re-
cruited from a local association (FM group, n = 26), 
and age- and gender-matched healthy patients were 
included as a control (control group, n = 26). The inclu-
sion criteria for the FM group were being diagnosed 
with FM syndrome in accordance with the criteria by 
the American College of Rheumatology (33), being 
older than 18 years of age, and properly understanding 
spoken and written Spanish. Criteria for exclusion were 
being diagnosed with a psychiatric disorder or suffer-
ing from a noncontrolled rheumatic pathology. The 
selection criteria to be met by the control group were 
the same with the exception of being diagnosed with 
FM. Patients were provided with detailed information 
about the protocol and signed informed consent before 
being enrolled. The intervention took place between 
August 20th and September 25th of 2019. The study 
was performed in accordance with the Declaration 
of Helsinki, was approved by the local ethics commit-
tee (14/2017), and was registered at ClinicalTrials.gov 
(NCT04047407). The study was conducted in accordance 
with the STROBE statement for observational studies in 
epidemiology. 
Protocol
We performed an observational, crossed-section 
study conducted in a single session. The following data 
were recorded: anthropometric (height, weight, and 
body mass index), sociodemographic (age and gender), 
and clinical-psychological [years since diagnosis, anxiety 
condition (34), pain catastrophizing (35), depression 
(36), and quality of life (37)]. Subsequently, the PPT was 
F ibromyalgia (FM) syndrome is a chronic, painful, noninflammatory rheumatic disease with high negative impact on quality of life (1,2). FM 
is characterized by widespread pain, fatigue, and 
generalized increased pain sensitivity on examination 
(3), the first of which is critical for its diagnosis (4-6), as 
well as psychological components, such as depression, 
pain catastrophizing, or kinesiophobia (7,8). Central 
sensitization (CS) is believed to be the common 
underlying mechanism to increased pain sensitivity 
and widespread areas of pain (9). For this reason, 
some authors (10-13) tend to employ terms, such as 
“sensitized central pain mechanisms” or “facilitated 
pain mechanisms,” instead of “central sensitization” to 
refer to facilitated pain responses in humans. 
Although FM symptoms can be explained within 
the theoretic framework of CS, to date, there are no 
assessment methods available to directly measure the 
activity of dorsal horn nociceptive neurons in humans. 
Nevertheless, surrogate pain models have been exten-
sively used in research investigating facilitated pain 
mechanisms in patients with FM, as well as in other 
chronic pain conditions. Appropriate and simple pain 
models are methods employed to assess pain mecha-
nisms that can potentially lead to improved treatments 
(14,15), as is the case for pressure pain thresholds 
(PPTs), which have been widely investigated in several 
diseases (16-26). These studies reported the presence 
of generalized increased sensitivity to pressure pain as 
an indicator of sensitized pain mechanisms. However, it 
has been suggested that PPTs might not be as useful as 
stimulation at suprathreshold intensities to assess pain 
mechanisms (27-29). 
Previous studies have used PPTs combined with 
mapping the referred pain area produced by pressure 
stimulation at suprathreshold intensities to assess pain 
mechanisms (30). An expansion in the referred pain 
area, as assessed in somatic structures, may reflect in-
creased sensitivity of pain mechanisms (21,31). Interest-
ingly, it has been suggested that the expansion of local 
pain and referred pain may share common mechanisms 
and be part of the same phenomenon (15). For these 
reasons, mapping of both local and referred pain has 
been singled out as a potential sensitive biomarker 
for pain mechanisms (31). To induce referred pain in a 
noninvasive manner, former studies have used intensi-
ties for pressure stimulation of 20% (31) and 30% (32) 
above the PPT by applying a tonic, nociceptive pressure 
stimulus on somatic structures. However, whether these 
findings apply for clinical populations that may be more 
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measured bilaterally at the supraspinatus, infraspinatus, 
lower trapezius, and gastrocnemius muscles. After a 
5-minute rest, the referred pain was evaluated by stimu-
lating the infraspinatus muscle of the dominant side us-
ing suprathreshold pressure at the same location where 
the PPT was established. The suprathreshold pressure 
stimulation was applied at 4 different stimulation in-
tensities (PPT +20%, +30%, +40%, and +50%) that were 
randomly administered in an ascending or descending 
order. The complete protocol was conducted with the 
patient in prone position. 
Pain Sensitivity
To record the PPT bilaterally, a manual pressure al-
gometer (Force Ten; Wagner Instruments, Riverside, CT) 
with a 1-cm2 probe was employed at 4 points (38): (1) 
supraspinatus muscle (1 cm cranial halfway at the spine 
of the scapula); (2) infraspinatus muscle (intermediate 
point between the inferior angle of the scapula, the 
spine of the scapula,  and medial angle of the scapula); 
(3) lower trapezius muscle (4–5 cm lateral to the apoph-
ysis of the spine at the seventh thoracic vertebra); and 
(4) gastrocnemius muscle (one-third distal to the medial 
gastrocnemius muscle). Pressure was raised until the pa-
tient indicated verbally that the feeling of pressure had 
become painful. This process was repeated 3 times with 
a minimum pause of 30 seconds between applications 
and the mean was calculated for posterior analysis. The 
value of each PPT was estimated in kg/cm2.
Pressure-Induced Referred Pain
Suprathreshold pressure stimulation was applied 
to the infraspinatus muscle of the dominant side at 
the location where the PPT was established using the 
same algometer. All patients received suprathreshold 
pressure stimulation at 4 different intensities: PPT +20% 
(120% PPT), +30% (130% PPT), +40% (140% PPT), and 
+50% (150% PPT), each lasting 60 seconds and with a 
minimum break of 5 minutes between stimulations to 
reestablish a normal response from the central nervous 
system (38). Stimuli were randomly applied in an ascend-
ing (from lower to higher intensity) or descending (from 
higher to lower intensity) order. After each stimulation, 
each patient was requested to mark the area in pain on 
a digital tablet using an application with a digitalized 
body chart (Navigate Pain; Aalborg University, Aalborg, 
Denmark) (39). Using digitalized drawings in tablets to 
mark areas in pain has been shown to be a valid and 
reliable method to assess these body regions, being 
comparable to paper records (40). The size of referred 
pain areas indicated by each patient was estimated in 
pixels.
The body chart was subdivided into 15 different 
regions (Fig. 1) (31,38): (1) the posterior head and neck 
area from the occipital process at the top to the cervi-
cothoracic junction at the bottom; (2) supraspinal area, 
limited by the base of the neck at C7 and the spine of 
the scapula; (3) pressure site area, overlying the infra-
spinatus area; (4) posterior shoulder, corresponding to 
the posterior deltoid muscle; (5) the back area, compris-
ing the ipsilateral part of the thoracic and lumbar spine 
below the infraspinatus area; (6) the posterior arm, 
namely the area between the posterior deltoid and 
the line joining the lateral and the medial epicondyles 
at the elbow; (7) the posterior forearm area, limited 
proximately by the olecranon and distally by the line 
joining the radial and ulnar styloid processes; (8) the 
posterior hand area, comprising the dorsal part of the 
hand; (9) the anterior head and neck area, from the 
anterior craniofacial region, including the anterior part 
of the neck down, up to the level of C7; (10) the supra-
clavicular area overlying the area from the clavicle to 
C7; (11) the chest area, marked by the sternum medi-
ally, the clavicle above, a vertical line from the axilla 
laterally, and the inferior part of the pectoralis major 
muscle below; (12) the anterior shoulder area, corre-
sponding to the anterior deltoid; (13) the anterior arm 
area, defined as the area between a horizontal line in-
ferior to the anterior deltoid muscle and a line joining 
the lateral and the medial epicondyles at the cubital 
fossa; (14) the anterior forearm, limited proximally by 
the cubital fossa and distally by the line joining the 
radial and ulnar styloid processes; and (15) the anterior 
hand area, comprising the volar side of the hand. The 
frequency with which pain occurred in each region was 
used for data analyses.
Additionally, patients were asked to value the pain 
intensity using a 100-mm-long Visual Analog Scale (VAS) 
(0 = absence of pain, 100 = maximally imaginable pain).
Statistical Analyses
Normality of variables was assessed via the Shap-
iro–Wilk test. Parametric variables were expressed by 
their mean (standard deviation) and nonparametric 
variables by their median (interquartile range). A 
2-way analysis of variance (ANOVA) test was employed 
to evaluate the extension of the referred pain area, in 
which the repeated measures were intensity (120%, 
130%, 140%, and 150% PPT) and size of referred pain 
areas reported on back, front, and full body images, 
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whereas a 1-way, repeated measures analysis of vari-
ance (RM-ANOVA) was used to analyze pain intensity 
on a VAS. The effect of the sequence (ascending or 
descending order of stimulation) was tested prior 
to clustering the data via an unpaired-measures test 
(Mann-Whitney U test).
Variables measuring the referred pain areas and 
total number of body regions were converted into 
logarithms to obtain a normal distribution of the data. 
The total number of body regions was analyzed via a 
1-way RM-ANOVA, whereas the frequency at which 
pain occurred in each body region was assessed via the 
Fisher exact test. Post hoc comparisons were conducted 
using the Wilcoxon signed-rank test with a Bonferroni 
correction. 
An exploratory correlation analysis (Pearson cor-
relation coefficient) was conducted to assess the re-
lationship between the referred pain data (following 
their logarithmic transformation) and anthropometric, 
clinical, and psychological variables.
Statistical significance was set at P < 0.05. Consid-
ering a moderate effect size of 0.25, 2 groups, 4 re-
peated measures, a power of 90%, and a conservative 
estimated correlation of 0.33 between repeated mea-
sures, the sample size was estimated to be 52 patients. 
Estimating an effect size of 1.19 for the area of pain in 
patients with FM compared with controls, a post hoc 
power analysis determined that this sample size was 
enough for detecting potential intergroup differences. 
The software used for power calculations was G*Power 
version 3.1.9.4, (University of Düsseldorf, Düsseldorf, 
Germany) (41).
Results
Baseline characteristics of the patients are shown in 
Table 1. No withdrawal was recorded during the process. 
Fig. 1. Sketch of  the 15 predefined body regions to quantify the extension of  referred pain following suprathreshold pressure 
stimulation on the infraspinatus muscle of  the dominant side.
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An effect of sequence (ascending or descending or-
der of stimulation) was observed on referred pain 
areas in the FM group at 150% PPT (Mann–Whitney 
U test: P = 0.019), but not in the control group.
Pain Sensitivity
Table 2 shows the recorded pain threshold 
values for both groups. The FM group registered 
lower PPTs than the control group (Student t-test, 
P = 0.0001).
Pressure-Induced Referred Pain
The referred pain areas were larger in the FM 
group compared with healthy patients: 120% PPT 
(Student t-test = 2.33, P = 0.024), 130% PPT (Stu-
dent t-test = 4.34, P = 0.001), 140% PPT (Student 
t-test = 4.02, P = 0.001), and 150% PPT (Student 
t-test = 7.48, P = 0.001) (Table 3).
Within the FM group, no differences were 
found between the intensity of suprathreshold 
pressure stimulation and the size of referred pain 
areas (RM-ANOVA: F(3.63) = 5.5, P = 0.135) or pain 
intensity (RM-ANOVA: F(3.75) = 2.78, P = 0.064) 
(Table 3). 
In the control group, differences were found 
in the total area of pain (front and rear view) when 
using different intensities to induce referred pain 
(RM-ANOVA: F(3.75) = 4.6, P = 0.005) (Table 3). The 
area of induced pain at 120% PPT was significantly 
lower than at 140% PPT (Bonferroni: P = 0.023). In 
terms of pain intensity as measured on the VAS, its 
value was significantly higher (RM-ANOVA: F(3.75) 
= 6.7; P = 0.0001) in the pressure ranges of 120% 
to 130% PPT (Bonferroni: P = 0.024) and 120% to 
150% PPT (Bonferroni: P = 0.004) (Table 3).
In terms of the frequency at which pain oc-
curred in each body area, the FM group showed 
a higher frequency in the following regions 
compared with the control group: anterior head/
neck, supraclavicular, chest, anterior shoulder, an-
terior arm, anterior forearm, posterior head/neck, 
supraspinal, posterior shoulder, posterior arm, 
and back (Table 4). Additionally, only patients in 
the FM group reported referred pain in the fol-
lowing regions: anterior thigh (15.4%), posterior 
thigh (11.5%), anterior leg (15.4%), posterior leg 
(11.5%), foot dorsal (11.5%), and foot sole (3.9%), 
which were not reported as painful areas in the 
control group in any case.
The total number of body regions affected by pain was 
greater in the FM group compared with the control group 
during each of the suprathreshold pressure stimulations (P 
= 0.0001) (Table 5). In this regard, differences in the inten-
sities to induce pain were observed both in the FM group 
(RM-ANOVA: F(3.60) = 3.7, P = 0.016) and the control (RM-
ANOVA: F(3.75) = 3.9, P = 0.011), and significance was not 
reached in the post hoc comparisons using the Wilcoxon test 
with Bonferroni correction (Table 5). 
Correlations
The potential association between the referred pain 
areas and anthropometric, clinical, and psychological vari-
ables was assessed, and a positive correlation was found 
between the body regions that experienced referred pain 
and pain catastrophizing in the FM group (Pearson r = 0.457, 
P = 0.032).
Table 1. Basal characteristics of  the sample. 
FM Group Control Group
N (% women) 26 (84.6) 26 (84.6)
Age (years) 55.6 ± 8.8 55.7 ± 8.9
Height (cm) 162.5 ± 7.2 163.9 ± 5.1
Weight (kg) 69.4 ± 10.9 67.6 ± 9.9
Body mass index 26.4 ± 3.6 25.1 ± 3.3
Time since diagnosis (years) 11.9 ± 7.5 -
Catastrophizing 21.0 [13.0–29.0] 2.5 [0–7.0]
Quality of life 61.9 ± 16.0 -
Anxiety 33.6 ± 11.2 -
Depression 15.5 [11.0–21.3] -
Data expressed by their mean ± standard deviation and median [inter-
quartile range]. 
Table 2. PPTs (mean ± standard deviation) bilaterally recorded 
for the 2 groups at the infraspinatus, supraspinatus, lower 
trapezius, and gastrocnemius muscles.
Muscle FM Control P
Supraspinatus
Dominant 1.54 ± 0.72 3.95 ± 1.21 0.0001
Nondominant 1.44 ± 0.51 3.94 ± 1.59 0.0001
Infraspinatus
Dominant 1.50 ± 0.70 3.93 ± 1.43 0.0001
Nondominant 1.52 ± 0.52 3.81 ± 1.67 0.0001
Lower 
trapezius 
Dominant 1.60 ± 0.67 4.55 ± 1.95 0.0001
Nondominant 1.55 ± 0.56 4.76 ± 2.18 0.0001
Gastrocnemius
Dominant 1.98 ± 0.84 3.95 ± 1.73 0.0001
Nondominant 2.18 ± 1.01 4.35 ± 1.83 0.0001
The values of PPT are expressed in kg/cm2.
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discussion
This study is the first to explore the use of pressure-
induced referred pain as a biomarker for sensitized pain 
mechanisms in patients suffering from FM syndrome. 
These patients reported referred pain body areas that 
were similar in size independently of the intensity of 
the applied suprathreshold pressure stimulation (120%, 
130%, 140%, and 150% PPT). In contrast, the size of 
the referred pain areas increased in the control group 
only when the pressure was at 140% PPT, whereas pain 
intensity was not significantly greater. The potential 
contribution of these findings to the understanding of 
pain mechanisms in FM syndrome and their application 
to clinical practice are discussed hereafter. This study 
presents some limitations, among which is the variabil-
ity found in the referred pain areas. 
Pain Sensitivity
Patients suffering from FM presented a higher sen-
sitivity to pain than those in the control group. These 
results are along the lines of findings from other studies 
that assessed the increase in pain sensitivity in musculo-
skeletal pain syndromes typically associated to CS, such 
as whiplash (16,17), tension-type headache (19,20), low 
back pain (21,22), osteoarthritis (23,24), carpal tunnel 
syndrome (25), or lateral epicondylalgia (26). Sensitized 
central pain mechanisms have been suggested to be 
common in both the increased pain sensitivity experi-
enced by patients with FM and the earlier mentioned 
syndromes (9) in which different types of factors can 
play a role, such as altered descending modulation, 
psychological components, and changes in the pres-
ence of nociceptive neurotransmitters [increased levels 
of substance P (42,43), excitatory amino-acids (44), and 
Table 3. Median [interquartile range] area of  pain after a 60-second pressure stimulation on the infraspinatus muscle of  the dominant side.
Pain Area
120% PPT 130% PPT 140% PPT 150% PPT P
Pairwise comparisons*
1-2 1-3 1-4 2-3 2-4 3-4
FM 13,602 [5,669–23,869] 15,167 [5,603–23,645] 16,072 [6,581–28,396] 14,386 [7,306–33,892] 0.135 ns ns ns ns ns ns
Control 1,356 [615–2,443] 1,835 [619–6,288] 2,520 [1,101–5,840] 1,845 [765–5,268] 0.005 ns < ns ns ns ns
Pain Intensity
120% PPT 130% PPT 140% PPT 150% PPT P
Pairwise comparisons*
1-2 1-3 1-4 2-3 2-4 3-4
FM 6.1 ± 1.7 6.3 ± 2.0 5.7 ± 1.9 6.8 ± 1.7 0.064 ns ns ns ns ns ns
Control 3.7 ± 1.5 4.4 ± 1.9 4.3 ± 1.9 4.8 ± 2.0 0.000 < ns < ns ns ns
The area is expressed by the number of pixels out of a total 602,931. Mean ± standard deviation pain intensity following a 60-second pressure stimulation 
on the infraspinatus muscle of the dominant side. *Bonferroni-adjusted pairwise comparisons: the symbol < indicates a significant difference (P < 0.05); ns, 
nonsignificant difference (P > 0.05).
Table 4. Percentage of  patients (n = 26 in each group) that 
reported pain in the different body regions when sustained 
pressure stimulation was applied on the infraspinatus muscle of  
the dominant side.
FM Control
Anterior head/neck 30.8 3.9*
Supraclavicular 34.6 3.9*
Chest 42.3 3.9*
Anterior shoulder 53.9 19.2*
Anterior arm 46.1 15.4*
Anterior forearm 30.8 3.9*
Anterior hand 26.9 7.7
Posterior head/neck 61.5 7.7*
Supraspinal area 88.5 15.4*
Infraspinatus 100.0 84.6
Posterior shoulder 92.3 53.8*
Posterior arm 80.8 34.6*
Posterior forearm 50.0 26.9
Posterior hand 42.3 23.1
Back 84.6 3.9*
*indicates a significant difference (P < 0.05).
Table 5. Median [interquartile range] body regions following a 
60-second pressure stimulation on the infraspinatus muscle of  
the dominant side.
Body Regions
PPT FM Control P
120% 4.0 [2.5–7.0] 1.0 [1.0–2.0] < 0.001
130% 5.0 [2.5–8.0] 1.0 [1.0–3.0] < 0.001
140% 5.0 [3.0–9.0] 2.0 [1.0–3.3] < 0.001
150% 5.0 [4.0–8.0] 1.0 [1.0–3.0] < 0.001
The final value expresses the number of regions out of a total of 15.
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neurotrophins (45) in the cerebrospinal fluid of patients 
with FM]. 
However, peripheral mechanisms have also been 
suggested to account for high pain sensitivity, such as 
increased levels of substance P in muscle tissue (46). 
Moreover, spontaneously active C nociceptors (type IB) 
have been found in patients with FM in proportions 
similar to painful neuropathies and painful small-fiber 
neuropathies, which seems to be the only parameter 
that correlates with neuropathy painfulness (47). These 
similarities found between FM and peripheral neu-
ropathies support the hypothesis that this spontaneous 
activity observed in the nociceptors C of peripheral 
nerves in patients with FM is enough to explain the 
pain sensations they experience (47). This outcome is 
in agreement with former studies that concluded that 
nociceptors C are directly involved in increased pain 
sensitivity (48-50), and hence their continuous stimula-
tion contributes not only to its intensity but also to its 
development into chronic pain (51).
Pressure-Induced Referred Pain
Referred pain is likely driven by both peripheral 
and central mechanisms as it can be evoked in areas 
where the sensory input has ceased (52,53). Experimen-
tal pressure-induced referred pain has been suggested 
as a useful biomarker for assessing increased pain sen-
sitivity of central pain mechanisms (31), and has been 
shown to be comparable to more traditional models, 
such as saline-induced pain, yet much less invasive, 
safer, and clinically transferable (31).
The aim of this study was to assess the distribution 
of referred pain areas evoked by different intensities 
of suprathreshold pressure stimulation in patients with 
FM. This method has been previously employed in 
trials (31,38) but never in patients suffering from FM 
syndrome. 
Contrary to the outcome in the control group of this 
study, the referred pain areas described by patients in the 
FM group did not differ significantly at different pressure 
intensities. A series of neuroplastic changes are related 
to the sensitized pain mechanisms described for patients 
with FM syndrome, both at a peripheral [spontaneous 
activity of nociceptors C, such as type IB (47)] and at a cen-
tral level [altered descending modulation, psychological 
factors, and changes in the concentration of nociceptive 
neurotransmitters (9,42-45)]. These changes produce an 
increase in pain sensitivity and can be involved in caus-
ing referred pain in multiple spinal segments (41,53). As 
a result, a slight pressure could result in areas of referred 
pain comparable to those produced by stronger pressures. 
This finding suggests that a mechanical stimulus slightly 
above the pain threshold can be a sufficient, simple, and 
safe method to assess the increased pain sensitivity that 
patients with FM experience.
Despite the known importance of sensitized pain 
mechanisms as a physiopathological basis for FM, the 
contribution of psychological factors cannot be obvi-
ated in these patients, which often experience depres-
sion, pain catastrophizing, or kinesiophobia (7,8). These 
cognitive and affective aspects are capable of influenc-
ing pain perception via the modulation of descending 
pathways (54) and are related to the amplification 
and extension of pain (55-58). The analysis conducted 
in this study on the correlation between the size of 
referred pain areas following suprathreshold pressure 
stimulation and psychological variables (depression, 
pain catastrophizing, and anxiety) showed a moderate 
direct association with pain catastrophizing. Thus it can 
be indirectly concluded that extensive areas of referred 
pain following suprathreshold pressure stimulation can 
indicate a greater level of catastrophizing and even 
become a predictive factor for it, revealing that these 
patients experience more grief and/or negative expec-
tations in the face of a painful experience. Along these 
lines, former studies have found that high values of 
pain catastrophizing correlate negatively with the per-
formance of descending modulatory systems (59), and 
that catastrophizing has a significant influence on the 
function of the prefrontal-dorsolateral cortex, which is 
related to pain modulation (60,61). 
Clinical Implications and Future Research
The findings of this research show that referred 
pain induced by applying suprathreshold pressure stim-
ulation can be a useful biomarker to assess the increase 
in pain sensitivity experienced by patients suffering 
from FM, with a 120% PPT being enough to assess pain 
mechanisms in FM. Future research could replicate this 
trial in other musculoskeletal pain syndromes typically 
associated with increased pain sensitivity and sensitized 
pain mechanisms, and also assess if the variability in the 
size of referred pain areas can provide a useful tool to 
assess the effectiveness of FM treatments.
conclusions
The observed outcome suggests that a suprathresh-
old pressure stimulation of 120% PPT can be useful for 
evaluating sensitized pain mechanisms in patients with 
FM.
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